Vandortuzumab vedotin

Overview

Diagram of vedotin antibody-drug conjugates

Vandortuzumab vedotin is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. It combines a monoclonal antibody specific to a target antigen on cancer cells with a potent cytotoxic agent, monomethyl auristatin E (MMAE), linked via a protease-cleavable linker. This allows for targeted delivery of the cytotoxic agent to cancer cells, minimizing damage to normal tissues.

Mechanism of Action

Vandortuzumab vedotin targets the CD70 antigen, which is overexpressed in various malignancies, including certain types of lymphoma and renal cell carcinoma. Upon binding to CD70, the ADC is internalized by the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

Development and Clinical Trials

Vandortuzumab vedotin has been evaluated in several clinical trials to assess its safety and efficacy. Early-phase trials have shown promising results in terms of tumor response rates and manageable toxicity profiles. Ongoing studies aim to further define its role in the treatment of CD70-positive malignancies.

Side Effects

Common side effects of vandortuzumab vedotin include peripheral neuropathy, fatigue, nausea, and myelosuppression. These side effects are consistent with those observed with other vedotin-based ADCs, due to the action of MMAE on dividing cells.

Related pages

• Antibody-drug conjugate
• Monomethyl auristatin E
• CD70
• Cancer treatment